RAFAEL HOLDINGS, INC. Available-for-sale Securities, Amortized Cost Basis
RAFAEL HOLDINGS, INC. (RFL) had Available-for-sale Securities, Amortized Cost Basis of $19.82 million as of 2018-10-31, per its 10-Q filed 2018-12-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-10-04
- 2018-10-31: Available-for-sale Securities, Amortized Cost Basis $19.82M.
- 2018-07-31: Available-for-sale Securities, Amortized Cost Basis $25.01M.
- 2018-04-30: Available-for-sale Securities, Amortized Cost Basis $31.25M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-10-31 | $19.82M 10-Q · filed 2018-12-10 |
| 2018-07-31 | $25.01M 10-K · filed 2019-10-04 |
| 2018-04-30 | $31.25M 10-Q · filed 2018-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |